Taysha Gene Therapies Stock Price

-0.02 (-0.12%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Taysha Gene Therapies Inc TSHA NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.02 -0.12% 17.29 20:00:00
Open Price Low Price High Price Close Price Prev Close
17.22 16.72 17.58 17.29 17.31
Bid Price Ask Price Spread News
10.00 21.05 11.05 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
2,296 118,255 $ 17.24 $ 2,038,203 - 16.72 - 33.84
Last Trade Time Type Quantity Stock Price Currency
18:40:43 1 $ 17.29 USD


Draw Mode:

Taysha Gene Therapies Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 655.59M 37.92M 16.49M $ - $ - -2.71 -5.60
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - 106.17k 26.70%

more financials information »

Taysha Gene Therapies News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical TSHA Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week19.8419.8416.7217.89103,298-2.55-12.85%
1 Month21.1121.462816.7219.50179,496-3.82-18.1%
3 Months21.8526.9916.7222.36210,203-4.56-20.87%
6 Months26.7831.6016.7222.89139,903-9.49-35.44%
1 Year22.2533.8416.7222.95151,381-4.96-22.29%
3 Years22.2533.8416.7222.95151,381-4.96-22.29%
5 Years22.2533.8416.7222.95151,381-4.96-22.29%

Taysha Gene Therapies Description

Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.

Your Recent History
Taysha Gen..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.